Investor Overview

Natera

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.

News

Recent News

Natera Announces New Prospera™ Data at ATC Showcasing Innovation in Cell-Free DNA  -  5/26/2020
New research on background cell-free DNA to refine transplant rejection risk SAN CARLOS, Calif. , May 26, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its Prospera donor-derived cell-free DNA More »
Natera Announces New Data at ASCO Highlighting Utility of Personalized MRD Monitoring  -  5/19/2020
Results from the first large, real-world study in 535 gastrointestinal (GI) cancer patients using Signatera™ MRD testing New data using Signatera to monitor treatment response with an immunotherapy-based regimen in hepatocellular carcinoma SAN CARLOS, Calif. More »
Natera and Illumina Settle Patent Dispute  -  5/18/2020
SAN CARLOS, Calif. and SAN DIEGO , May 18, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, and Illumina Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing platforms, today announced that they have settled their patent More »
Natera to Present at the UBS Virtual Global Healthcare Conference  -  5/13/2020
SAN CARLOS, Calif. , May 13, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the UBS Virtual Global Healthcare Conference on Monday, May 18, 2020 at 12:50 p.m. PT ( 3:50 p.m. ET ). More »
Prospera™ Receives Positive Medicare Coverage  -  5/11/2020
SAN CARLOS, Calif. , May 11, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Noridian, a Medicare Administrative Contractor (MAC), has issued positive coverage for the Prospera donor-derived cell-free DNA (dd-cfDNA) test. More »
Event

Upcoming Events

More events are coming soon.
Events

Past events

Date
Title

Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.